Preclinical Studies Of Glucocorticoid Receptor Antagonists In The Treatment Of Alcohol Dependence | 18036
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2464

Journal of Addiction Research & Therapy received 2464 citations as per Google Scholar report

Journal of Addiction Research & Therapy peer review process verified at publons
Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • SafetyLit
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Preclinical studies of glucocorticoid receptor antagonists in the treatment of alcohol dependence

3rd International Conference and Exhibition on Addiction Research & Therapy

Lynda Sharrett-Field, Little HJ, Shaw SG and Prendergast MA

Plenary Session: J Addict Res Ther

DOI: 10.4172/2155-6105.S1.015

G lucocorticoid levels are markedly altered by acute and prolonged exposure to intoxicating doses of ethanol, yet the behavioral significance of these alterations are not fully understood. Prior work has shown that ethanol withdrawal associated cognitive deficits in mice can be reduced by acute administration of a glucocorticoid receptor (GR) antagonist and we have also shown that chronic ethanol consumption increases the brain concentrations of corticosterone in rodents. Our in vitro work has shown that corticosterone increases alcohol withdrawal neurotoxicity and calcium accumulation in hippocampal neurons. Our current work focuses on the ability ofglucocorticoid antagonist drugs to reduce the behavioural consequences of alcohol withdrawal. Administration of one dose of the Type 2 GR antagonist, mifepristone, immediately after alcohol withdrawal, prevented the subsequent memory deficits in mice and significantly lowered withdrawal signs. Repeated doses of this drug, given torats during a 4-day binge alcohol treatment, substantially reduced the acute signs of alcohol withdrawal. We have also studied the effects of the mifepristone analogue, ORG34517 that is more selective and lacks progesterone antagonist action. This compound significantly reduced acute withdrawal signs in rats and memory deficits in mice when given prior to withdrawal from chronic alcohol treatment. As a whole, these findings suggest that GR may represent therapeutic targets to be exploited in the treatment of ethanol dependence
Sharrett-Field L received her Bachelor of Science degree in Psychology from the University of Southern Indiana in 2008. She completed Master of Science degree in Experimental Psychology with expertise in behavioral neuroscience in 2010 and a Doctor of Philosophy degree in this discipline in 2013. She has extensive expertise in biochemical, surgical and behavioral approaches to the study of alcohol addiction and its treatment. Her publications reflect a focus on understanding how glucocorticoid hormone receptor systems are altered by alcohol exposure, employing both in vitro and in vivo models, and how these systems may be pharmacologically exploited in the treatment of alcohol dependence